Back to All

Diaceutics and SEAP collaborate on new study: Impact of the ESGO and ICCR guidelines in the diagnosis of endometrial cancer in Spain!

2 June, 2021

Diaceutics, with the collaboration of Dr. Xavier Matías-Guiu (president of SEAP and president-elect of the International Society of Gynaecological Pathologists) has conducted the study "Impact of the ESGO and ICCR guidelines in the diagnosis of endometrial cancer in Spain", with the aim to obtain a vision of the current diagnostic approach in endometrial cancer in terms of biomarker analysis in Spain , as well as to assess the impact of the latest recommendation guidelines prepared by the ESGO and the ICCR on the evolution of the diagnosis of this pathology, with special emphasis on the effect of these guidelines on the implementation of MMR analysis.

Endometrial carcinoma (EC) is the most common gynaecological cancer in developed countries. The importance of biomarker testing in EC is increasing, with more biomarkers gaining relevance for the diagnosis and managing of this disease. Specifically, the latest international guidelines highlight the importance of Mismatch Repair Deficiency (MMRd) testing in EC.

A survey with questions about biomarker testing in endometrial cancer was distributed among the participating laboratories, focusing on Pathology services of public hospitals. Information about what biomarkers are routinely tested in endometrial cancer, including testing methodologies and algorithms, and emphasizing MMRd and Microsatellite Instability (MSI) testing, was captured.

Highlights of the study

  • Mismatch Repair deficiency (MMRd) analysis is gaining relevance in endometrial cancer.
  • MMRd analysis by immunohistochemistry in ALL endometrial cancer samples is a common practice in Spain.
  • MSI analysis by molecular methods is a less frequent strategy in endometrial cancer.
  • Other biomarkers such as POLE are also becoming more relevant in this disease.

Get more information about trends on biomarker testing on endometrial cancer in the full report* available exclusively to DXRX members.

*Direct link will work for DXRX members only. If you cannot access the report using the above link, please visit our signup page or email [email protected] and one of our customer support team will assist you.

About Diaceutics

At Diaceutics we believe that every patient should get the precision medicine they deserve. We are a data analytics and end-to-end services provider enabled by DXRX - the world’s first Network solution for the development and commercialization of precision medicine diagnostics. 

Diaceutics has worked on every precision medicine brought to market and provides services to 36 of the world’s leading pharmaceutical companies. We have built the world’s largest repository of diagnostic testing data with a growing network of 2500 labs in 51 countries.

Public Relations & Investor Relations advisers

Alma PR
71-73 Carter Lane

Tel: +44 (0)20 3405 0205 or [email protected]

Caroline Forde
Robyn Fisher
Kieran Breheny